What is your presentation about?
I shall be presenting data on prevalence of depression, suicidal ideation and self-harm. I shall be discussing what constitutes self-harm in diabetes and how that can be identified. The presentation will also explore the challenges with identification and coding of suicidal events and what this means for our ability to provide appropriate support to both people with diabetes and to health care professionals supporting them.
What makes this topic important in 2022?
Depression, closely associated with suicidal ideation, is diagnosed in 7-25% of the United States and European populations. Individuals with type 1 diabetes (T1D) have a two- to three-times higher prevalence of depression and approximately double the rate of suicide compared to the general population. Rates of self-harm and suicide among people with diabetes are likely to be considerably underestimated due to poor identification.
How did you become involved with this area of diabetes research or care?
I was asked by the FDA to establish a collaborative community aimed at reducing incidents of intended self-injury and suicide amongst people with diabetes. I have worked in this field for a number of years.
What are you most looking forward to at the 82nd Scientific Sessions?
There are some fantastic symposia scheduled, so looking forward to learning about the latest developments in diabetes treatments and technologies. Also looking forward to being back in-person and networking with colleagues.